Hemotransmissive Infections Testing Market Size, Share, Trends & Forecast

The Hemotransmissive Infections Testing Market is expanding as healthcare systems strengthen blood safety and infectious disease screening programs. The market is estimated at USD 2.8 billion in 2025 and is projected to reach USD 8.3 billion by 2035, registering an 11.6% CAGR. Rising awareness of bloodborne infections, regulatory requirements, and demand for accurate testing are supporting market development. 

Molecular diagnostics and nucleic acid testing are becoming increasingly important in infection screening. Automated platforms can process larger sample volumes while supporting consistent testing workflows, and advances in diagnostic technologies are helping laboratories improve the speed and sensitivity of pathogen detection. 

HBV DNA, HCV RNA, and HIV RNA testing represent the major test categories within the market. Hepatitis B testing is a leading indication, supported by the need for early detection, routine screening, and monitoring, while comprehensive blood-screening programs continue to create demand across healthcare facilities. 

Hospitals represent the largest end-use segment, accounting for an estimated 50% of market revenue in 2025. Blood banks, diagnostic centers, and clinics also contribute to demand as healthcare providers strengthen screening protocols and adopt centralized or automated testing systems. 

Future opportunities may emerge from high-throughput molecular platforms, automated laboratory workflows, and software-enabled diagnostic systems. Greater integration of multi-pathogen testing, digital laboratory management, and public-health screening programs could further support the expansion of hemotransmissive infection testing worldwide. 

Read More
Lukoon https://lukoon.com